NeutriSci International (FRA:1N9) WACC %:70.85% (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NeutriSci International WACC %?

NeutriSci International FRA:1N9 WACC % is 70.85% as of Jul. 18, 2026.

As of today (2026-07-18), NeutriSci International's weighted average cost of capital is 70.85%%. NeutriSci International's ROIC % is 0.00% (calculated using TTM income statement data). NeutriSci International earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


NeutriSci International  (FRA:1N9) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, NeutriSci International's weighted average cost of capital is 70.85%%. NeutriSci International's ROIC % is 0.00% (calculated using TTM income statement data). NeutriSci International earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

NeutriSci International WACC % Historical Data

* Premium members only.

The historical data trend for NeutriSci International's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeutriSci International WACC % Chart

NeutriSci International Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.11 11.62 14.94 13.05 8.51

NeutriSci International Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.43 8.51 9.42 -0.08 -3.33

FRA:1N9 vs ZTS, NBIX: WACC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, NeutriSci International's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeutriSci International WACC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NeutriSci International's WACC % distribution charts can be found below:

* The bar in red indicates where NeutriSci International's WACC % falls into.



NeutriSci International WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, NeutriSci International's market capitalization (E) is €0.590 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Sep. 2023, NeutriSci International's latest one-year quarterly average Book Value of Debt (D) is €0.1262 Mil.
a) weight of equity = E / (E + D) = 0.590 / (0.590 + 0.1262) = 0.8238
b) weight of debt = D / (E + D) = 0.1262 / (0.590 + 0.1262) = 0.1762

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 3.42%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. NeutriSci International's beta is 13.7079.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 3.42% + 13.7079 * 6% = 85.6674%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Sep. 2023, NeutriSci International's interest expense (positive number) was €0.002 Mil. Its total Book Value of Debt (D) is €0.1262 Mil.
Cost of Debt = 0.002 / 0.1262 = 1.5848%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -0.382 = 0%.

NeutriSci International's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.8238*85.6674%+0.1762*1.5848%*(1 - 0%)
=70.85%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 70.85% mean?
NeutriSci International (FRA:1N9) has a WACC % of 70.85% as of Jul. 18, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on NeutriSci International and its competitors.
Is NeutriSci International's WACC % too high?
NeutriSci International's current WACC % is 70.85%. The Drug Manufacturers industry median WACC % is 9.00. NeutriSci International's value of 70.85% is 687.2% above this industry median.
How does NeutriSci International's WACC % compare to ZTS and NBIX?
NeutriSci International's WACC % of 70.85% can be compared against companies in the Drug Manufacturers industry. The industry median WACC % is 9.00. NeutriSci International's value of 70.85% is 687.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Drug Manufacturers company?
The median WACC % among Drug Manufacturers companies is 9.00, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeutriSci International's current WACC % of 70.85% is 687.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on NeutriSci International and its competitors. For the Drug Manufacturers industry, the median WACC % is 9.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeutriSci International's current WACC % is 70.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeutriSci International stock overvalued right now?
NeutriSci International (FRA:1N9) has a current WACC % of 70.85%. The current WACC % is 70.85% and 687.2% above the Drug Manufacturers industry median of 9.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For NeutriSci International (FRA:1N9), the current WACC % is 70.85% as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeutriSci International Business Description

Address 609 Granville Street, Suite 1600, Vancouver, BC, CAN, V7Y 1C3
NeutriSci International Inc specializes in the production and formulation of nutraceutical products within the B2B industry. By incorporating natural ingredients, it implements industry disrupting patent pending Cryolization Technology to provide B2B partners with the ability to create unparalleled products. Using patent pending proprietary ingredients, technologies, and IP, it can help bring to market effective, solution-oriented products that meet the needs of consumers. The company continues to develop emerging sales channels in the USA, European, Asian & South American markets.